$ABBV
AbbVie Inc. Stock $abbv

$abbv Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000155115224000020 Filed on May 03, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue	$14.46B	$12.31B	$12.23B
YoY Change	4.31%	0.7%	-9.7%
Cost Of Revenue	$4.202B	$4.094B	$3.971B
YoY Change	0.24%	3.1%	-2.0%
Gross Profit	$10.26B	$8.216B	$8.254B
YoY Change	6.07%	-0.46%	-12.99%
Gross Profit Margin	70.94%	66.74%	67.52%
Selling, General & Admin	$3.377B	$3.315B	$2.995B
YoY Change	6.4%	10.68%	-4.22%
% of Gross Profit	32.91%	40.35%	36.29%
Research & Development	$1.948B	$1.939B	$2.290B
YoY Change	12.73%	-15.33%	52.97%
% of Gross Profit	18.99%	23.6%	27.74%
Depreciation & Amortization	$184.0M	$183.0M	$179.0M
YoY Change	-3.16%	2.23%	-9.6%
% of Gross Profit	1.79%	2.23%	2.17%
Operating Expenses	$5.325B	$5.254B	$5.275B
YoY Change	12.51%	-0.4%	14.08%
Operating Profit	$3.998B	$2.798B	$2.979B
YoY Change	-19.07%	-6.08%	-36.85%
Interest Expense	$726.0M	$660.0M	-$489.0M
YoY Change	-247.86%	-234.97%	-189.23%
% of Operating Profit	18.16%	23.59%	-16.41%
Other Income/Expense, Net	-$1.345B	-$586.0M	-$1.804B
YoY Change	-4.75%	-67.52%	-332.47%
Pretax Income	$2.146B	$1.755B	$475.0M
YoY Change	-17.78%	269.47%	-90.36%
Income Tax	$773.0M	$383.0M	$234.0M
% Of Pretax Income	36.02%	21.82%	49.26%
Net Earnings	$1.370B	$1.369B	$239.0M
YoY Change	-32.31%	472.8%	-94.68%
Net Earnings / Revenue	9.47%	11.12%	1.96%
Basic Earnings Per Share	$0.77	$0.77	$0.13
Diluted Earnings Per Share	$0.77	$0.77	$0.13
COMMON SHARES
Basic Shares Outstanding	1.766B shares	1.766B shares	1.769B shares
Diluted Shares Outstanding	1.771B shares	1.773B shares	1.776B shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$13.16B	$18.07B	$6.722B
YoY Change	50.09%	168.8%	-11.23%
Cash & Equivalents	$13.13B	$18.07B	$6.711B
Short-Term Investments	$27.00M	$2.000M	$11.00M
Other Short-Term Assets	$4.717B	$4.608B	$4.460B
YoY Change	3.9%	3.32%	-5.53%
Inventory	$4.218B	$4.245B	$3.833B
Prepaid Expenses
Receivables	$11.72B	$11.95B	$11.47B
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$33.82B	$38.87B	$26.49B
YoY Change	17.21%	46.75%	-0.08%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.023B	$4.980B	$4.931B
YoY Change	1.62%	0.99%	-2.84%
Goodwill	$33.39B	$33.43B	$32.22B
YoY Change	3.61%	3.74%	-0.24%
Intangibles	$60.24B	$62.23B	$64.85B
YoY Change	-4.17%	-4.04%	-12.35%
Long-Term Investments	$272.0M	$305.0M	$257.0M
YoY Change	-5.56%	18.68%	-1.15%
Other Assets	$9.197B	$9.067B	$5.800B
YoY Change	48.39%	56.33%	14.11%
Total Long-Term Assets	$108.1B	$110.0B	$108.1B
YoY Change	1.51%	1.8%	-7.41%
TOTAL ASSETS
Total Short-Term Assets	$33.82B	$38.87B	$26.49B
Total Long-Term Assets	$108.1B	$110.0B	$108.1B
Total Assets	$141.9B	$148.9B	$134.5B
YoY Change	4.85%	10.65%	-6.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$29.33B	$31.33B	$24.79B
YoY Change	8.48%	26.37%	9.84%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$3.000M	$1.000M
YoY Change		200.0%	-91.67%
Long-Term Debt Due	$12.59B	$10.19B	$2.800B
YoY Change	141.9%	264.04%	-71.83%
Total Short-Term Liabilities	$41.92B	$41.52B	$27.59B
YoY Change	30.01%	50.5%	-15.16%
LONG-TERM LIABILITIES
Long-Term Debt	$58.05B	$63.81B	$59.29B
YoY Change	4.01%	7.61%	-6.66%
Other Long-Term Liabilities	$32.43B	$32.78B	$32.25B
YoY Change	0.41%	1.64%	15.08%
Total Long-Term Liabilities	$32.43B	$32.78B	$32.25B
YoY Change	0.41%	1.64%	15.08%
TOTAL LIABILITIES
Total Short-Term Liabilities	$41.92B	$41.52B	$27.59B
Total Long-Term Liabilities	$32.43B	$32.78B	$32.25B
Total Liabilities	$74.34B	$74.30B	$59.84B
YoY Change	15.2%	24.17%	-1.16%
SHAREHOLDERS EQUITY
Retained Earnings	-$3.768B	-$2.384B	$2.393B
YoY Change	-310.62%	-199.62%	-53.11%
Common Stock	$20.88B	$20.66B	$19.62B
YoY Change	5.24%	5.29%	4.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$7.838B	$7.829B	$6.524B
YoY Change	20.07%	20.0%	42.29%
Treasury Stock Shares
Shareholders Equity	$6.778B	$8.007B	$13.27B
YoY Change
Total Liabilities & Shareholders Equity	$141.9B	$148.9B	$134.5B
YoY Change	4.85%	10.65%	-6.05%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	$1.370B	$1.369B	$239.0M
YoY Change	-32.31%	472.8%	-94.68%
Depreciation, Depletion And Amortization	$184.0M	$183.0M	$179.0M
YoY Change	-3.16%	2.23%	-9.6%
Cash From Operating Activities	$2.271B	$4.040B	$4.193B
YoY Change	-64.06%	-3.65%	-14.57%
INVESTING ACTIVITIES
Capital Expenditures	$241.0M	$193.0M	$175.0M
YoY Change	35.39%	10.29%	8.02%
Acquisitions		$9.199B	$0.00
YoY Change
Other Investing Activities	-$861.0M	$6.000M	-$26.00M
YoY Change	428.22%	-123.08%	-83.12%
Cash From Investing Activities	-$1.102B	-$9.588B	-$499.0M
YoY Change	223.17%	1821.44%	-68.64%
FINANCING ACTIVITIES
Cash Dividend Paid		$2.772B	$2.661B
YoY Change		4.17%	5.34%
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-6.097B	$10.82B	-$6.192B
YoY Change	55.54%	-274.73%	-11.19%
NET CHANGE
Cash From Operating Activities	2.271B	$4.040B	$4.193B
Cash From Investing Activities	-1.102B	-$9.588B	-$499.0M
Cash From Financing Activities	-6.097B	$10.82B	-$6.192B
Net Change In Cash	-4.928B	$5.253B	-$2.490B
YoY Change	-339.46%	-310.96%	-31.74%
FREE CASH FLOW
Cash From Operating Activities	$2.271B	$4.040B	$4.193B
Capital Expenditures	$241.0M	$193.0M	$175.0M
Free Cash Flow	$2.030B	$3.847B	$4.018B
YoY Change	-66.94%	-4.26%	-15.34%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001551152
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	us-gaap	Investment Type Extensible Enumeration InvestmentTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#MoneyMarketFundsMember
CY2023Q4	us-gaap	Investment Type Extensible Enumeration InvestmentTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#MoneyMarketFundsMember
CY2023Q1	us-gaap	Collaborative Arrangement Transaction Statement Of Income Or Comprehensive Income Extensible Enumeration CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#Revenues
CY2024Q1	us-gaap	Collaborative Arrangement Transaction Statement Of Income Or Comprehensive Income Extensible Enumeration CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#Revenues
CY2024Q1	us-gaap	Collaborative Arrangement Transaction Statement Of Income Or Comprehensive Income Extensible Enumeration CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#Revenues
CY2023Q1	us-gaap	Collaborative Arrangement Transaction Statement Of Income Or Comprehensive Income Extensible Enumeration CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#Revenues
CY2024Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1765867781	shares
CY2024Q1	us-gaap	Revenues Revenues	12310000000	usd
CY2023Q1	us-gaap	Revenues Revenues	12225000000	usd
CY2024Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4094000000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3986000000	usd
CY2024Q1	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	164000000	usd
CY2023Q1	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	150000000	usd
CY2024Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	0	usd
CY2023Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	10000000	usd
CY2024Q1	us-gaap	Costs And Expenses CostsAndExpenses	9512000000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	9457000000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	2798000000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	2768000000	usd
CY2024Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-453000000	usd
CY2023Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-454000000	usd
CY2024Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-4000000	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-35000000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-586000000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1804000000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1755000000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	475000000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	383000000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	234000000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	1372000000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	241000000	usd
CY2024Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	3000000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	2000000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	1369000000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	239000000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.77
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.13
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.77
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.13
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1769000000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1770000000	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1773000000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1776000000	shares
CY2024Q1	us-gaap	Profit Loss ProfitLoss	1372000000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	241000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-20000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	12000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-396000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	194000000	usd
CY2024Q1	abbv	Other Comprehensive Income Loss Net Investment Hedge Tax OtherComprehensiveIncomeLossNetInvestmentHedgeTax	57000000	usd
CY2023Q1	abbv	Other Comprehensive Income Loss Net Investment Hedge Tax OtherComprehensiveIncomeLossNetInvestmentHedgeTax	-60000000	usd
CY2024Q1	abbv	Other Comprehensive Income Loss Net Investment Hedge Gain Loss After Reclassificationand Tax OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax	207000000	usd
CY2023Q1	abbv	Other Comprehensive Income Loss Net Investment Hedge Gain Loss After Reclassificationand Tax OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax	-224000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax	-1000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax	-14000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-10000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-38000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax	7000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax	-4000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	30000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-41000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-149000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-33000000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	1223000000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	208000000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	3000000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	2000000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1220000000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	206000000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18067000000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12814000000	usd
CY2024Q1	us-gaap	Short Term Investments ShortTermInvestments	2000000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	2000000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11949000000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11155000000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	8007000000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	10360000000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	4245000000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	4099000000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	4608000000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	4932000000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	38871000000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	33002000000	usd
CY2024Q1	us-gaap	Long Term Investments LongTermInvestments	305000000	usd
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	304000000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4980000000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4989000000	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	62225000000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	55610000000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	33426000000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	32293000000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	9067000000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	8513000000	usd
CY2024Q1	us-gaap	Assets Assets	148874000000	usd
CY2023Q4	us-gaap	Assets Assets	134711000000	usd
CY2024Q1	us-gaap	Short Term Borrowings ShortTermBorrowings	3000000	usd
CY2023Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	0	usd
CY2024Q1	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	10193000000	usd
CY2023Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	7191000000	usd
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	31326000000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	30650000000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	41522000000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	37841000000	usd
CY2024Q1	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	63805000000	usd
CY2023Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	52194000000	usd
CY2024Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2722000000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1952000000	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	32778000000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	32327000000	usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	4000000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	4000000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1829957662	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1823046087	shares
CY2024Q1	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	18000000	usd
CY2023Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	18000000	usd
CY2024Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	64234512	shares
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	57105354	shares
CY2024Q1	us-gaap	Treasury Stock Value TreasuryStockValue	7829000000	usd
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	6533000000	usd
CY2024Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	20656000000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	20180000000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2384000000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1000000000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2454000000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2305000000	usd
CY2024Q1	us-gaap	Minority Interest MinorityInterest	40000000	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	37000000	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8047000000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	10397000000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	148874000000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	134711000000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	17287000000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	239000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-33000000	usd
CY2023Q1	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	2630000000	usd
CY2023Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	1955000000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	399000000	usd
CY2023Q1	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	-4000000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	13303000000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	10397000000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	1369000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-149000000	usd
CY2024Q1	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	2753000000	usd
CY2024Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	1324000000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	504000000	usd
CY2024Q1	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	3000000	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8047000000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	1372000000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	241000000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	183000000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	179000000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1891000000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1948000000	usd
CY2024Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-389000000	usd
CY2023Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-267000000	usd
CY2024Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	660000000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1872000000	usd
CY2024Q1	us-gaap	Payment For Contingent Consideration Liability Operating Activities PaymentForContingentConsiderationLiabilityOperatingActivities	391000000	usd
CY2023Q1	us-gaap	Payment For Contingent Consideration Liability Operating Activities PaymentForContingentConsiderationLiabilityOperatingActivities	14000000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	348000000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	313000000	usd
CY2024Q1	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	164000000	usd
CY2023Q1	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	150000000	usd
CY2024Q1	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2023Q1	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	710000000	usd
CY2024Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	45000000	usd
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	128000000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	702000000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	195000000	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	75000000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	185000000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-284000000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	167000000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	362000000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-451000000	usd
CY2024Q1	us-gaap	Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable	378000000	usd
CY2023Q1	us-gaap	Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable	187000000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	4040000000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	4193000000	usd
CY2024Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	9199000000	usd
CY2023Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
CY2024Q1	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	190000000	usd
CY2023Q1	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	353000000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	193000000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	175000000	usd
CY2024Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	6000000	usd
CY2023Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	19000000	usd
CY2024Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	6000000	usd
CY2023Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	22000000	usd
CY2024Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	6000000	usd
CY2023Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-26000000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9588000000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-499000000	usd
CY2024Q1	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	5008000000	usd
CY2023Q1	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	0	usd
CY2024Q1	us-gaap	Repayments Of Other Short Term Debt RepaymentsOfOtherShortTermDebt	5005000000	usd
CY2023Q1	us-gaap	Repayments Of Other Short Term Debt RepaymentsOfOtherShortTermDebt	0	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	14963000000	usd
CY2024Q1	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	103000000	usd
CY2023Q1	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	1351000000	usd
CY2024Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	99000000	usd
CY2023Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
CY2024Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	2772000000	usd
CY2023Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	2661000000	usd
CY2024Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1324000000	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1955000000	usd
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	127000000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	65000000	usd
CY2024Q1	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	usd
CY2023Q1	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	311000000	usd
CY2024Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	24000000	usd
CY2023Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	21000000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10819000000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-6192000000	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-18000000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8000000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5253000000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2490000000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12814000000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9201000000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18067000000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6711000000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	660000000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	553000000	usd
CY2024Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	207000000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	99000000	usd
CY2024Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-453000000	usd
CY2023Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-454000000	usd
CY2024Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1258000000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1356000000	usd
CY2024Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1890000000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1643000000	usd
CY2024Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1097000000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1100000000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	4245000000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	4099000000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11725000000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11635000000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6745000000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6646000000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4980000000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4989000000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	29890000000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	183000000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	179000000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	1369000000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	239000000	usd
CY2024Q1	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Basic ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic	10000000	usd
CY2023Q1	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Basic ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic	11000000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1359000000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	228000000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1769000000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1770000000	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.77
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.13
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	1369000000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	239000000	usd
CY2024Q1	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Diluted ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted	10000000	usd
CY2023Q1	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Diluted ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted	11000000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	1359000000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	228000000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1769000000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1770000000	shares
CY2024Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	4000000	shares
CY2023Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	6000000	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1773000000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1776000000	shares
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.77
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.13
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	60645000000	usd
CY2024Q1	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	190000000	usd
CY2023Q1	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	353000000	usd
CY2024Q1	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	164000000	usd
CY2023Q1	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	150000000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	32293000000	usd
CY2024Q1	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	1249000000	usd
CY2024Q1	us-gaap	Goodwill Other Increase Decrease GoodwillOtherIncreaseDecrease	-116000000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	33426000000	usd
CY2024Q1	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	0	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	90535000000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	83333000000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	28026000000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	55307000000	usd
CY2024Q1	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	1580000000	usd
CY2024Q1	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	1580000000	usd
CY2023Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	303000000	usd
CY2023Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	303000000	usd
CY2024Q1	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	92115000000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	29890000000	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	62225000000	usd
CY2023Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	83636000000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	28026000000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	55610000000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1900000000	usd
CY2024Q1	us-gaap	Gain Loss From Components Excluded From Assessment Of Cash Flow Hedge Effectiveness Net GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet	0	usd
CY2023Q1	us-gaap	Gain Loss From Components Excluded From Assessment Of Fair Value Hedge Effectiveness Net GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet	0	usd
CY2023Q1	us-gaap	Gain Loss From Components Excluded From Assessment Of Cash Flow Hedge Effectiveness Net GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet	0	usd
CY2024Q1	us-gaap	Gain Loss From Components Excluded From Assessment Of Fair Value Hedge Effectiveness Net GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet	0	usd
CY2024Q1	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	99000000	usd
CY2023Q4	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	66000000	usd
CY2024Q1	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	428000000	usd
CY2023Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	496000000	usd
CY2024Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0	usd
CY2024Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	0	usd
CY2024Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0	usd
CY2024Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0	usd
CY2023Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	19890000000	usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	16384000000	usd
CY2024Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-660000000	usd
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-1872000000	usd
CY2024Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	391000000	usd
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	325000000	usd
CY2024Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	20159000000	usd
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	17931000000	usd
CY2024Q1	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	161000000	usd
CY2023Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	159000000	usd
CY2024Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.22
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	348000000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	313000000	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	60000000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	55000000	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	288000000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	258000000	usd
CY2024Q1	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	3900000000	usd
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.49
CY2024Q1	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023Q1	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2024Q1	us-gaap	Decrease In Unrecognized Tax Benefits Is Reasonably Possible DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible	162000000	usd
CY2024Q1	us-gaap	Revenues Revenues	12310000000	usd
CY2023Q1	us-gaap	Revenues Revenues	12225000000	usd

Files In Submission

Name	View Source	Status
0001551152-24-000020-index-headers.html	Edgar Link	pending
0001551152-24-000020-index.html	Edgar Link	pending
0001551152-24-000020.txt	Edgar Link	pending
0001551152-24-000020-xbrl.zip	Edgar Link	pending
abbv-20240331.htm	Edgar Link	pending
abbv-20240331.xsd	Edgar Link	pending
abbv-20240331xex101.htm	Edgar Link	pending
abbv-20240331xex101001.jpg	Edgar Link	pending
abbv-20240331xex101002.jpg	Edgar Link	pending
abbv-20240331xex101003.jpg	Edgar Link	pending
abbv-20240331xex101004.jpg	Edgar Link	pending
abbv-20240331xex101005.jpg	Edgar Link	pending
abbv-20240331xex101006.jpg	Edgar Link	pending
abbv-20240331xex101007.jpg	Edgar Link	pending
abbv-20240331xex101008.jpg	Edgar Link	pending
abbv-20240331xex101009.jpg	Edgar Link	pending
abbv-20240331xex101010.jpg	Edgar Link	pending
abbv-20240331xex101011.jpg	Edgar Link	pending
abbv-20240331xex101012.jpg	Edgar Link	pending
abbv-20240331xex101013.jpg	Edgar Link	pending
abbv-20240331xex101014.jpg	Edgar Link	pending
abbv-20240331xex101015.jpg	Edgar Link	pending
abbv-20240331xex101016.jpg	Edgar Link	pending
abbv-20240331xex101017.jpg	Edgar Link	pending
abbv-20240331xex101018.jpg	Edgar Link	pending
abbv-20240331xex102.htm	Edgar Link	pending
abbv-20240331xex102001.jpg	Edgar Link	pending
abbv-20240331xex102002.jpg	Edgar Link	pending
abbv-20240331xex102003.jpg	Edgar Link	pending
abbv-20240331xex102004.jpg	Edgar Link	pending
abbv-20240331xex102005.jpg	Edgar Link	pending
abbv-20240331xex102006.jpg	Edgar Link	pending
abbv-20240331xex102007.jpg	Edgar Link	pending
abbv-20240331xex102008.jpg	Edgar Link	pending
abbv-20240331xex102009.jpg	Edgar Link	pending
abbv-20240331xex102010.jpg	Edgar Link	pending
abbv-20240331xex102011.jpg	Edgar Link	pending
abbv-20240331xex102012.jpg	Edgar Link	pending
abbv-20240331xex102013.jpg	Edgar Link	pending
abbv-20240331xex102014.jpg	Edgar Link	pending
abbv-20240331xex102015.jpg	Edgar Link	pending
abbv-20240331xex102016.jpg	Edgar Link	pending
abbv-20240331xex102017.jpg	Edgar Link	pending
abbv-20240331xex103.htm	Edgar Link	pending
abbv-20240331xex103001.jpg	Edgar Link	pending
abbv-20240331xex103002.jpg	Edgar Link	pending
abbv-20240331xex103003.jpg	Edgar Link	pending
abbv-20240331xex103004.jpg	Edgar Link	pending
abbv-20240331xex103005.jpg	Edgar Link	pending
abbv-20240331xex103006.jpg	Edgar Link	pending
abbv-20240331xex103007.jpg	Edgar Link	pending
abbv-20240331xex103008.jpg	Edgar Link	pending
abbv-20240331xex104.htm	Edgar Link	pending
abbv-20240331xex104001.jpg	Edgar Link	pending
abbv-20240331xex104002.jpg	Edgar Link	pending
abbv-20240331xex104003.jpg	Edgar Link	pending
abbv-20240331xex104004.jpg	Edgar Link	pending
abbv-20240331xex104005.jpg	Edgar Link	pending
abbv-20240331xex104006.jpg	Edgar Link	pending
abbv-20240331xex104007.jpg	Edgar Link	pending
abbv-20240331xex104008.jpg	Edgar Link	pending
abbv-20240331xex104009.jpg	Edgar Link	pending
abbv-20240331xex104010.jpg	Edgar Link	pending
abbv-20240331xex104011.jpg	Edgar Link	pending
abbv-20240331xex104012.jpg	Edgar Link	pending
abbv-20240331xex104013.jpg	Edgar Link	pending
abbv-20240331xex104014.jpg	Edgar Link	pending
abbv-20240331xex104015.jpg	Edgar Link	pending
abbv-20240331xex104016.jpg	Edgar Link	pending
abbv-20240331xex104017.jpg	Edgar Link	pending
abbv-20240331xex105.htm	Edgar Link	pending
abbv-20240331xex105001.jpg	Edgar Link	pending
abbv-20240331xex105002.jpg	Edgar Link	pending
abbv-20240331xex105003.jpg	Edgar Link	pending
abbv-20240331xex105004.jpg	Edgar Link	pending
abbv-20240331xex105005.jpg	Edgar Link	pending
abbv-20240331xex105006.jpg	Edgar Link	pending
abbv-20240331xex105007.jpg	Edgar Link	pending
abbv-20240331xex105008.jpg	Edgar Link	pending
abbv-20240331xex105009.jpg	Edgar Link	pending
abbv-20240331xex105010.jpg	Edgar Link	pending
abbv-20240331xex105011.jpg	Edgar Link	pending
abbv-20240331xex105012.jpg	Edgar Link	pending
abbv-20240331xex105013.jpg	Edgar Link	pending
abbv-20240331xex105014.jpg	Edgar Link	pending
abbv-20240331xex105015.jpg	Edgar Link	pending
abbv-20240331xex311.htm	Edgar Link	pending
abbv-20240331xex312.htm	Edgar Link	pending
abbv-20240331xex321.htm	Edgar Link	pending
abbv-20240331xex322.htm	Edgar Link	pending
abbv-20240331_g1.jpg	Edgar Link	pending
abbv-20240331_g2.gif	Edgar Link	pending
abbv-20240331_def.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
abbv-20240331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
abbv-20240331_htm.xml	Edgar Link	completed
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
abbv-20240331_lab.xml	Edgar Link	unprocessable
abbv-20240331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABBV
AbbVie Inc. Stock $abbv

2024 Q2 Form 10-Q Financial Statement

#000155115224000020 Filed on May 03, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABBV AbbVie Inc. Stock $abbv

2024 Q2 Form 10-Q Financial Statement

#000155115224000020 Filed on May 03, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABBV
AbbVie Inc. Stock $abbv